$The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma$

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma

Relapsed and refractory (R/R) multiple myeloma (MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short. In patients with R/R MM after therapy of bortezomib and/or immunomodulators a bendamusti...

Full description

Bibliographic Details
Main Authors:	S. V. Voloshin, S. S. Bessmeltsev, T. P. Zagoskina, N. V. Medvedeva, K. D. Kaplanov, E. V. Karyagina, A. D. Garifullin, A. Yu. Kuvshinov, L. V. Stelmashenko, K. M. Abdulkadyrov
Format:	Article
Language:	Russian
Published:	ABV-press 2015-10-01
Series:	Онкогематология
Subjects:	multiple myeloma bendamustine bortezomib lenalidomide stem cells transplantation genetic abnormalities
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/149

Similar Items

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
by: Norbert Grzasko, et al.
Published: (2021-11-01)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib‐based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients
by: Yuka Kawaji‐Kanayama, et al.
Published: (2022-02-01)

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
by: Fevzi Fırat Yalnız, et al.
Published: (2017-08-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Advances in multiple myeloma therapy during two past decades
by: Ivan Spicka
Published: (2014-06-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

Evaluating the difference in clinical efficacy for t(11;14) multiple myeloma patients with CD20- or CD20+
by: ZHAO Weihong, HUANG Bintao, LIU Rui, XIANG Caixia
Published: (2023-09-01)

Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience
by: İbrahim Halil Açar, et al.
Published: (2023-08-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

New drugs in the therapy of multiple myeloma Novas drogas na terapia do mieloma múltiplo
by: Antonio Palumbo, et al.
Published: (2008-06-01)

Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
by: Susana Aceituno, et al.
Published: (2018-06-01)

The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma
by: Michael A. Firer, et al.
Published: (2021-08-01)

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01)

How I manage frontline transplant-eligible multiple myeloma in Italy
by: Vittorio Montefusco, et al.
Published: (2020-09-01)

Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma
by: Liang Zhou
Published: (2022-03-01)

BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
by: A. S. Kolbin, et al.
Published: (2015-06-01)

Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma
by: Alpay Yeşilaltay, et al.
Published: (2024-01-01)

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM
by: Friederike Bachmann, et al.
Published: (2021-03-01)

Pomalidomide in the management of relapsed/refractory multiple myeloma: A review
by: Sergej Semochkin
Published: (2023-08-01)

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
by: Panagiotis Samaras, et al.
Published: (2015-02-01)

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
by: Maryam Pourabdollah, et al.
Published: (2016-11-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
by: Pınar Ataca Atilla, et al.
Published: (2019-11-01)

Integrating novel agents into multiple myeloma treatment – current status in Switzerland and treatment recommendations
by: Swiss Medical Weekly
Published: (2010-04-01)

Integrating novel agents into multiple myeloma treatment – current status in Switzerland and treatment recommendations
by: C Taverna, et al.
Published: (2010-09-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
by: Felipe de Arriba de la Fuente, et al.
Published: (2022-12-01)

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
by: Anna Furlan, et al.
Published: (2024-04-01)

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States
by: Rohan Medhekar, et al.
Published: (2022-08-01)